Factor V Leiden, Prothrombin and MTHFR Mutation in Patients with Preeclamsia, Intrauterine Growth Restriction and Placental Abruption

Vesna Livrinova; Marija Hadzi Lega; Anita Hristova Dimcheva; Igor Samardziski; Rozalinda Isjanovska

doi:10.3889/oamjms.2015.099

Authors

Vesna Livrinova University Clinic for Obstetrics and Gynecology, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje
Marija Hadzi Lega University Clinic for Obstetrics and Gynecology, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje
Anita Hristova Dimcheva Institute for Transfusion Medicine, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje
Igor Samardziski University Clinic for Obstetrics and Gynecology, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje
Rozalinda Isjanovska Institute for Epidemiology and Medical Biostatistics, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje

DOI:

https://doi.org/10.3889/oamjms.2015.099

Keywords:

factor V Leiden, prothrombin, MTHFR, preeclampsia, IUGR, placental abruption

Abstract

BACKGROUND: Factor V Leiden, Prothrombin and MTHFR gene mutation, could have an influence in pregnancy with adverse outcome Preeclamsia, IUGR and Placental abruption.

AIM: The aim of this study is to investigate the presence of above mentioned inherited thrombophilias and its statistical significance, distribution among the complicated and normal pregnancy, and relative risk for carrier of mutation to develop preeclampsia, IUGR and placental abruption.

MATERIAL AND METHODS: Prospective cohort study is implemented at University Clinic for Obstetric and Gynecology in Skopje, Republic of Macedonia. The study included 109 delivered patients: 40 with preeclapmsia, 22 with IUGR, 17 with placental abruption and 30 as control group with normal pregnancy. The amount of 3 ml venous blood has been used for detection of these point mutations using ThromboStrip -Opegen, QIAGEN kit manufactured for thrombotic risk.

RESULTS: The highest frequency was found: in the group with preeclampsia 35% were MTHFR homozygous, IUGR -MTHFR heterozygous 45%, Placental abruption- 52.9% MTHFR heterozygous, and in the control group without thrombophilia 56.7%. There were combined thrombophilia in 3 patients. There aren`t statistical significance in presence of thrombophilia among groups (p > 0.05). Statistical significance (p < 0.05) was found between carriers of MTHFR homozygous in preeclampsia and group with placental abruption and control group. Relative risk in IUGR group for MTHFR homozygous was 5.54 (1.37<RR<22.4). Relative risk in placental abruption for Factor V Leiden heterozygous was 4.50 (0.47<RR<42.75).

CONCLUSION: The presence of mutation MTHFR homozygous could increase the risk for development of IUGR and mutation of Factor V Leiden for placental abruption. Further investigations with more patients are warranted.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Calman R, et al. Basic Principle and Clinical Practice, 5th edition, Walter Kluwer, 2005.

Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222-31.

http://dx.doi.org/10.1056/NEJM200104193441607 DOI: https://doi.org/10.1056/NEJM200104193441607

PMid:11309638

Esman ET. The Dyoteinic anticoagulanth pathway â€“ Arterio Sclerosis. Thrombophilia. 1992;12:135.

Dahblack B. Resistance to activated C caused by the Factor V Mutation, common to risk factor for venous thrombosis. Thromb Haemost. 1997; 78: 438. DOI: https://doi.org/10.1055/s-0038-1657574

Berhina RP et al. Associated mutation in coagulation factor V, associated with resistant to APC. Nature. 1994; 369: 64-67.

http://dx.doi.org/10.1038/369064a0 DOI: https://doi.org/10.1038/369064a0

PMid:8164741

Distefano et al. Screening for inherited thrombophilia.Indication and therapeutical implification. Haematologica. 2002; 87:1095-1108.

Franko RF, Reidsma Ph. Genetic Risk Factor of Venous Thrombosis. Human Genet. 2001; 109:369-84.

http://dx.doi.org/10.1007/s004390100593 DOI: https://doi.org/10.1007/s004390100593

PMid:11702218

Arsov T, Miladinovic D, Spiroski M. Factor V Leiden is associated with Deep Venous Thrombosis of Large Blood vessel. Croat Med J. 2006; 47:433-439.

PMid:16758522 PMCid:PMC2080416

Di Srefano, Rossi E et al. Screening for inherited thrombophilia: Indications and therapeutical implications. Haemathologica. 2002;87:1095-1108.

Gerhard A, et al. Prothrombin and Factor V Leiden mutation in women with history of thrombosis during pregnancy and puerperium. N Engl J Med. 2000; 342:374-380.

http://dx.doi.org/10.1056/NEJM200002103420602 DOI: https://doi.org/10.1056/NEJM200002103420602

PMid:10666427

Martinelli P, Grandone E et al. Familial Thrombophilia and the occurrence of fetal growth restriction. Haemathologica. 2001;86:428-431.

Karegard M, Gennsen G. Incidence and recurrence rate of abruptio placentae in Sweden. Obstet Gynecol. 1996;175:902-905.

Kupferminc M, et al. Increased frequency of genetic thrombophilia in women with complication of pregnancy. N English Journal of Medicine. 1999;340:9-13.

http://dx.doi.org/10.1056/NEJM199901073400102 DOI: https://doi.org/10.1056/NEJM199901073400102

PMid:9878639

Mello G, et al. Usefulness of screening for congenital or acquired haemostatic abnormalities in women with previous complicated pregnancy. Haemost. 1999;29:197â€“203. DOI: https://doi.org/10.1159/000022502

Many A, Schreiber et al. Pathological feature of the placenta in women with sever pregnancy complications and Trombophylia. Obstetrics and Gynecology .2001; 98: 1041-44. DOI: https://doi.org/10.1097/00006250-200112000-00010

http://dx.doi.org/10.1016/S0029-7844(01)01621-0 DOI: https://doi.org/10.1016/S0029-7844(01)01621-0

Lindoff C et al. Preeclampsia is associated with reduce response to activated protein C. Am J Obstet Gynecol. 1997;176:457-460.

http://dx.doi.org/10.1016/S0002-9378(97)70515-5 DOI: https://doi.org/10.1016/S0002-9378(97)70515-5

D'Elia AV, Driul L, Giacomello R, Colaone R, Fabbro D, Di Leonardo C, Florio P, Petraglia F, Marchesoni D, Damante G. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol Obstet Invest. 2002;53(2):84-7.

http://dx.doi.org/10.1159/000052998 DOI: https://doi.org/10.1159/000052998

PMid:11961379

Duchez F, Goffinet S, Degre P, Fournet. Thrombophilia and fetal growth restriction. Europian Journal of Ob and Gynecology. 2002; 36-40.

Dilley A. Thrombosis in pregnancy: The role of Factor V Leiden, protrombin gen and MTHFR in US population. Thromb Haemost. 1995;551-552.

Dordjevic V. Mutacija Faktor V Leiden, F II G 20210A i MTHTR C677T kod tromboza duboki vena u toku trudnoce sa praeklampsijama. Vojno Med Pregled. 2005; 3:201-205.

Infante-Rivard C, Rivard GE, Yotov WV et al. Association of thrombophilia polymorphism with intrauterine growth restriction. N Engl J Med. 2002;347:19-25.

http://dx.doi.org/10.1056/NEJM200207043470105 DOI: https://doi.org/10.1056/NEJM200207043470105

PMid:12097536

Wiener-Megnasi Z, Ben Shlomo I, Shalev I. Resistance to activated protein C and Leiden mutation:High prevalence in women with sever pregnancy complication. Obst Gynecol. 2001; 97:753 â€“ 759.

Zootz RP, Gerthardt A. Inherited Thrombophilia and Gestational Venous Tromboembolism. Best Pract Res Clin Haematology. 2003;16:243-259.

http://dx.doi.org/10.1016/S1521-6926(03)00022-7 DOI: https://doi.org/10.1016/S1521-6926(03)00022-7

Grandone E, Margaglione M, Colaizzo D, et al. Gene succeptibility to pregnant related venous thrombembolism: Roles of factor V Leiden prothombin G20210A and MTHFR mutation. Am J Obstet Gynecology. 1998;179:1324-1328.

http://dx.doi.org/10.1016/S0002-9378(98)70155-3 DOI: https://doi.org/10.1016/S0002-9378(98)70155-3

Lin L, August P. Genetic Thrombophilias and preeclampsia: a meta analysis. Obstet Gynecol. 2003; 105:182-192.

http://dx.doi.org/10.1097/01.AOG.0000146250.85561.e9 DOI: https://doi.org/10.1097/01.AOG.0000146250.85561.e9

PMid:15625161